Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed/Cisplatin as Pre-operative Chemotherapy in Stage IIIA N2 NSCLC
NCT01165021Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2010
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Primary endpoint: Overall Response Rate up to 9 weeks. Started Nov 2010; status: completed.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01165021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01165021.